Baseline characteristics of AIS patients treated with EVT in the pre-pandemic and pandemic groups
| Pre-pandemic group | Pandemic group | OR (95% CI) | P value | |
| Gender, male, n (%) | 22 (64.7) | 15 (71.4) | 1.104 (0.765 to 1.594) | 0.606 |
| Age, mean±SD, years | 65.2±13.1 | 62.3±12.8 | NA | 0.431 |
| Hypertension, n (%) | 20 (58.8) | 16 (76.2) | 1.295 (0.895 to 1.874) | 0.188 |
| Diabetes mellitus, n (%) | 12 (35.3) | 6 (28.6) | 0.810 (0.358 to 1.829) | 0.606 |
| Hyperlipidemia, n (%) | 2 (5.9) | 0 | NA | 0.519 |
| Coronary heart disease, n (%) | 9 (26.5) | 3 (14.3) | 0.540 (0.165 to 1.770) | 0.467 |
| Myocardial infarction, n (%) | 2 (5.9) | 0 | NA | 0.519 |
| Atrial fibrillation, n (%) | 9 (26.5) | 6 (28.6) | 1.079 (0.449 to 2.597) | 0.865 |
| Cerebral infarction, n (%) | 2 (5.9) | 3 (14.3) | 2.429 (0.442 to 13.354) | 0.359 |
| Anticoagulation, n (%) | 5 (14.7) | 0 | NA | 0.174 |
| Antiplatelet, n (%) | 1 (2.9) | 0 | NA | 1.000 |
| Pulmonary inflammation on chest CT, n (%) | NA | 6 (28.6) | NA | NA |
| Pre-NIHSS score, median (IQR) | 13 (11–17) | 12 (11–18) | NA | 0.537 |
| ASPECTS, median (IQR) | 9 (8–10) | 9 (8–10) | NA | 0.727 |
| Anterior circulation, n (%) | 28 (82.4) | 13 (61.9) | 0.752 (0.519 to 1.088) | 0.091 |
| Stroke etiology | ||||
| Cardioembolic, n (%) | 15 (44.1) | 9 (42.9) | 0.971 (0.521 to 1.810) | 0.249 |
| Large vessel atherosclerosis, n (%) | 13 (38.2) | 11 (52.4) | 1.370 (0.759 to 2.473) | |
| Tandem lesion, n (%) | 5 (14.7) | 0 | NA | |
| Dissection, n (%) | 1 (2.9) | 1 (4.8) | 1.619 (0.107 to 24.526) | |
| Use of rt-PA | 12 (35.3) | 11 (52.4) | 1.484 (0.806 to 2.734) | 0.212 |
| Onset to hospital arrival, median (IQR), min | 322 (166–420) | 253 (191–441) | NA | 0.315 |
AIS, acute ischemic stroke; ASPECTS, Alberta Stroke Program Early CT score; EVT, endovascular thrombectomy; IQR, interquartile range (25–75%); NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen activator.